ASG. Aurora Spine Corp

Aurora Spine Announces Leadership Promotions: Matt Paxton, Executive Vice President of Sales and Katelyn Sims, Area Vice President of Commercialization and Key Accounts

Aurora Spine Announces Leadership Promotions: Matt Paxton, Executive Vice President of Sales and Katelyn Sims, Area Vice President of Commercialization and Key Accounts

CARLSBAD, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the promotion of Matt Paxton to Executive Vice President of Sales and Katelyn Sims to Area Vice President of Commercialization and Key Accounts. These strategic appointments underscore Aurora Spine’s commitment to developing world-class talent. Both Matt and Katelyn’s commitment to excellence, innovation, and delivering exceptional patient outcomes have been the cornerstone of their success.

Mr. Paxton and Ms. Sims embody Aurora Spine’s purpose-driven mentality, bringing a relentless focus on innovation and patient-centric care to their new roles. Through their dedication and hard work, both leaders have played pivotal roles in advancing Aurora Spine’s mission to revolutionize spinal healthcare with cutting-edge solutions that improve the quality of life for patients worldwide.

As Executive Vice President of Sales, Mr. Paxton will spearhead company-wide initiatives, leveraging his expertise to drive operational excellence and strategic growth. Over the years, Mr. Paxton has demonstrated an unwavering commitment to Aurora Spine’s vision, playing a key role in fostering a culture of collaboration, innovation, and accountability.

Ms. Sims, as Area Vice President of Commercialization and Key Accounts, will oversee the implementation of dynamic sales and market strategies, ensuring that Aurora Spine’s groundbreaking products continue to reach healthcare providers and patients in need. With a proven track record of building strong partnerships and a passion for making a difference, Ms. Sims is poised to elevate Aurora Spine’s impact across the healthcare ecosystem.

“Aurora Spine’s success is rooted in the dedication of our team, and Matt and Katelyn exemplify the leadership we need to achieve our ambitious goals for 2025,” said Matthew Goldstone, Chief Commercialization Officer of Aurora Spine. “Their commitment to innovation and patient outcomes will undoubtedly propel our company forward as we continue to disrupt the spine care industry.”

Both promotions reflect Aurora Spine’s strategic focus on enhancing its leadership team to capitalize on the opportunities ahead. The company remains steadfast in its mission to develop transformative products and solutions that address unmet needs in spinal healthcare. With a focus on simplifying complex spinal procedures, Aurora Spine’s advanced product portfolio is trusted by healthcare professionals worldwide to deliver superior outcomes for their patients.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant and pain care markets through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at or .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation



Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Chad Clouse

Chief Financial Officer

(760) 424-2004

 



 
EN
22/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aurora Spine Corp

 PRESS RELEASE

Aurora Spine Corporation Announces Fourth Quarter and Fiscal Year 202...

Aurora Spine Corporation Announces Fourth Quarter and Fiscal Year 2024 Financial Results -Company reports record revenue of $17.6 million for FY 2024, an increase of 21% – -Company to host conference call Today, Tuesday, April 29th at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it...

 PRESS RELEASE

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fisca...

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it will issue its financial results for the fourth quarter and fiscal year ended December 31, 2024, on Monday, April 28, 2025, after market hours. Management will host a conference call for investors on Tuesday, April 29, 2025 at 11:00 am ET/8:00a...

 PRESS RELEASE

Aurora Spine Announces the Resignation of Board Director James Snow

Aurora Spine Announces the Resignation of Board Director James Snow CARLSBAD, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that James Snow, a board member for Aurora Spine since its inception in 2012, has resigned from the Aurora Spine Board of Directors to take on the role of Regulatory Affairs and Quality Assurance Manager for the Company. Mr. Snow will use his 20+ years of medical device expe...

 PRESS RELEASE

Aurora Spine Announces Publication of Biomechanical Study Demonstratin...

Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" i...

 PRESS RELEASE

Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion...

Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System CARLSBAD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s newest product, the AERO™ Facet Fusion System. The AERO MIS Facet Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering fr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch